secwatch.observer — SEC 8-K summary
======================================

Issuer:     TuHURA Biosciences, Inc./NV (HURA)
CIK:        0001498382
Form:       8-K
Filed at:   2024-11-25T23:59:59+00:00
Accession:  0000950170-24-130436
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TuHURA plans IFx-2.0 Phase 3 trial under SPA; signs non-binding LOI to acquire Kineta's KVA12123
--------------------------------------------------------------------------------

- IFx-2.0 Phase 3 accelerated approval trial in first-line MCC to start H1 2025 under FDA SPA, with ORR primary and PFS secondary endpoints.
- Non-binding LOI with Kineta to acquire KVA12123 VISTA antibody via merger; definitive agreement targeted Q4 2024.
- Cash runway expected to fund operations late into H2 2025; $31M from Kintara merger plus $5M for Kineta exclusivity.
- Hired Peter O'Neill as VP Clinical Operations and Michael Krsulich as Head of Quality Assurance.
- REM-001 photodynamic therapy study for cutaneous metastatic breast cancer enrollment expected to complete Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024130436/0000950170-24-130436-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1498382/000095017024130436/hura-20241125.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-130436

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer